Unicycive to Resubmit NDA for Oxylanthanum Carbonate by Year End

• Unicycive Therapeutics resubmits New Drug Application for oxylanthanum carbonate (OLC) by year-end • Presented analysis at American Society of Nephrology, demonstrating OLC reduces pill burden by 7x in volume and 2x in count • Ended Q3 with $42.7 million in cash and expected runway into 2027 • OLC significantly reduces pill burden compared to available phosphate binders.